Angela De Simone

Prof. Angela De Simone

Department of Drug Science and Technology, University of Turin, via P.Giuria 9, 10125 Torino, Italy
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2018 in Chromatographia
Verified
Journal Article
Closed access
PDF file
Angela De SimoneAngela De Simone
Angela De Simone
MNMarina Naldi
Marina Naldi
MBManuela Bartolini
Manuela Bartolini
LDLara Davani
Lara Davani
VAVincenza Andrisano
Vincenza Andrisano

21 March 2018 in Molecules
Verified
Journal Article
Open access
PDF file
DSDaniela Suchánková
Daniela Suchánková
KBKateřina Breiterová
Kateřina Breiterová
TSTomas Siatka
Tomas Siatka
KKKamila Klímová
Kamila Klímová
LDLara Davani
Lara Davani
Lucie CahlikovaLucie Cahlikova
Lucie Cahlikova
Glycogen synthase kinase-3β (GSK-3β) is a multifunctional serine/threonine protein kinase that was originally identified as an enzyme involved in the control of glycogen metabolism. It plays a key role in diverse physiological processes including metabolism, the cell cycle, and gene expression by regulating a wide variety of well-known substances like glycogen synthase, tau-protein, and β-catenin. Recent studies have identified GSK-3β as a potential therapeutic target in Alzheimer´s disease, bipolar disorder, stroke, more than 15 types of cancer, and diabetes. GSK-3β is one of the most attractive targets for medicinal chemists in the discovery, design, and synthesis of new selective potent inhibitors. In the current study, twenty-eight Amaryllidaceae alkaloids of various structural types were studied for their potency to inhibit GSK-3β. Promising results have been demonstrated by alkaloids of the homolycorine-{9-O-demethylhomolycorine (IC50 = 30.00 ± 0.71 µM), masonine (IC50 = 27.81 ± 0.01 μM)}, and lycorine-types {caranine (IC50 = 30.75 ± 0.04 μM)}.

3 April 2019 in Molecules
Verified
Journal Article
Open access
PDF file
EKEliška Kohelová
Eliška Kohelová
RPRozálie Peřinová
Rozálie Peřinová
NMNegar Maafi
Negar Maafi
Jan KorabecnyJan Korabecny
Jan Korabecny
DSDaniela Suchánková
Daniela Suchánková
Lucie CahlikovaLucie Cahlikova
Lucie Cahlikova
Twelve derivatives 1a–1m of the β-crinane-type alkaloid haemanthamine were developed. All the semisynthetic derivatives were studied for their inhibitory potential against both acetylcholinesterase and butyrylcholinesterase. In addition, glycogen synthase kinase 3β (GSK-3β) inhibition potency was evaluated in the active derivatives. In order to reveal the availability of the drugs to the CNS, we elucidated the potential of selected derivatives to penetrate through the blood-brain barrier (BBB). Two compounds, namely 11-O-(2-methylbenzoyl)-haemanthamine (1j) and 11-O-(4-nitrobenzoyl)-haemanthamine (1m), revealed the most intriguing profile, both being acetylcholinesterase (hAChE) inhibitors on a micromolar scale, with GSK-3β inhibition properties, and predicted permeation through the BBB. In vitro data were further corroborated by detailed inspection of the compounds’ plausible binding modes in the active sites of hAChE and hBuChE, which led us to provide the structural determinants responsible for the activity towards these enzymes.

1 May 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Federica BellutiFederica Belluti
Federica Belluti
Angela De SimoneAngela De Simone
Angela De Simone
ATAndrea Tarozzi
Andrea Tarozzi
MBManuela Bartolini
Manuela Bartolini
ADAlice Djemil
Alice Djemil
ARAngela Rampa
Angela Rampa

25 June 2022 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
SMSerena Montanari
Serena Montanari
LDLara Davani
Lara Davani
CTCristina Terenzi
Cristina Terenzi
MMMarco Maltoni
Marco Maltoni
VAVincenza Andrisano
Vincenza Andrisano
MRMarianna Ricci
Marianna Ricci

1 May 2021 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
SMS. Montanari
S. Montanari
LDL. Davani
L. Davani
VTV. Tumiatti
V. Tumiatti
MDM. Dimilta
M. Dimilta
AGA.V. Gaddi
A.V. Gaddi
VAVincenza Andrisano
Vincenza Andrisano